SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is undergoing a massive, volatile short squeeze that has left the community debating if the rally is a sustained mechanical dislocation or a house of cards nearing a blow-off top. Investors are actively discussing the stock's extreme short interest and low float relative to institutional ownership, with many monitoring for a potential secondary offering or sudden reversal while debating whether to jump in, hold, or short against the parabolic trend.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending as investors debate its long-term potential following recent regulatory approvals and strategic expansion efforts. While some in the community highlight the stock's significant upside from new institutional partnerships and infrastructure contracts, others express deep frustration with management's communication, the lack of formal earnings guidance, and ongoing concerns regarding dilution.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing extreme volatility and intense retail discussion following a government executive order to expedite psychedelic drug reviews. While bulls are driving the stock on speculation of a short squeeze and long-term potential for ibogaine, skeptics are actively warning of dilution risks and the company's history of erratic price movements.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is currently capturing attention as the community weighs the company's long-term potential in deep-sea mining against regulatory and geopolitical headwinds. Investors are actively debating the impact of upcoming production milestones and the necessity of US-based mineral sourcing, while closely monitoring institutional activity and options volume for signs of a potential short squeeze.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

BULL is gaining momentum as investors react to two major catalysts: the termination of the Yorkville SEPA contract, which removes significant sell-side pressure, and the approval of PDT rule changes by the SEC and FINRA. The community is actively discussing the stock's potential to mirror the performance of other brokerage peers, with many traders focused on breaking through key technical resistance levels while debating whether this marks the start of a sustained recovery.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending amid a surge in sector momentum and investor excitement following a strategic partnership with French rare-earth processor Carester, which aims to shorten the supply chain gap. The community is actively debating the stock's long-term potential as a vertically integrated domestic leader versus short-term risks like potential share dilution and sensitivity to geopolitical tensions.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is experiencing significant volatility driven by intense community debate over its sudden, parabolic price swings, which many traders are labeling as a classic pump-and-dump scheme. While some investors are actively scalping the momentum, others are highlighting concerns about the company's obscure business model and the heavy influx of bot-like activity on social platforms.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing increased investor attention and positive price momentum, driven by speculation over a potential buyout as the company nears key performance incentive deadlines. Traders are also closely monitoring expanded share buybacks and strong patient adoption data for Briumvi, fueling community optimism about the stock's long-term valuation and upcoming data catalysts.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp. is seeing heavy momentum following its IPO debut as investors flock to its specialized role in autonomous defense systems and drone technology. The community is actively debating the company's growth potential amid ongoing geopolitical tensions, with many highlighting its significant government backlog and comparing it to other high-growth players in the defense sector.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors weigh its role as a strategic domestic rare earth producer against recent broader market volatility and uncertainty regarding government pricing support. The community is actively discussing its long-term potential as a national security asset, balancing concerns over short-term downward price pressure with optimism for its upcoming 60 Minutes feature and future magnet production milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oppenheimer⬇️the PT on $SLNO to $80 and reiterated at Outperform. 
$RYTM $HRMY $XBI 
Oppenheimer said:::We have revised our SLNO model to project a slower US launch ramp vs. our prior estimates as well as reflect a go-it-alone scenario for European commercialization following recent mgmt commentary. 
 
Nonetheless, we remain above consensus on 2026 top-line, and see upcoming events (early May&#39;s 1Q update, EU regulatory opinion ~mid-year) as offering support to the shares which have underperformed the XBI by ~30% YTD and are down ~60% since their July 2025 highs. 
 
We see greater value creation through preservation of EU economics, and recognize that the de-risking of an EMA approval—particularly if the stock is slow to recover—could catalyze an acquisitive move by a global rare disease player. We reiterate our Outperform, but lower our PT to $80 (from $110).

H.C. Wainwright⬇️ $SLNO&#39;s PT to $100 and reiterated at a Buy rating. 
$RYTM $RLMD 
Here&#39;s what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2029170480448524463?s=20

H.C. Wainwright⬇️ $SLNO's PT to $100 and reiterated at a Buy rating.$RYTM $RLMDH.C. Wainwright said-Soleno Therapeutics recently reported its 4Q25 and full-year 2025 financial and operating results:(1) total 2025 VYKAT XR net sales totaled $190.4M, roughly in-line with our... https://t.co/AHEaV62p2s

quantumup on X (formerly Twitter): "H.C. Wainwright⬇️ $SLNO's PT to $100 and reiterated at a Buy rating.$RYTM $RLMDH.C. Wainwright said-Soleno Therapeutics recently reported its 4Q25 and full-year 2025 financial and operating results:(1) total 2025 VYK...

StockTwits Web

Soleno Therapeutics Inc

Rhythm Pharmaceuticals Inc.

Relmada Therapeutics Inc

Quantumup

Harmony Biosciences Holdings Inc

SPDR S&P Biotech ETF

 
Oppenheimer said:::We have revised our SLNO model to project a slower US launch ramp vs. our prior estimates as well as reflect a go-it-alone scenario for European commercialization following recent mgmt commentary. 
 
Nonetheless, we remain above consensus on 2026 top-line, and see upcoming events (early May's 1Q update, EU regulatory opinion ~mid-year) as offering support to the shares which have underperformed the XBI by ~30% YTD and are down ~60% since their July 2025 highs. 
 
We see greater value creation through preservation of EU economics, and recognize that the de-risking of an EMA approval—particularly if the stock is slow to recover—could catalyze an acquisitive move by a global rare disease player. We reiterate our Outperform, but lower our PT to $80 (from $110).